Douglas A. Treco

Filings by Douglas A. Treco span 3 companies, the busiest being Inozyme Pharma, Inc., Ra Pharmaceuticals, Inc. and CRISPR Therapeutics AG. In total, 11 filings cover trades dated from 1 February 2019 to 6 August 2025.

The open-market side counts 1 purchase for €978k alongside 2 sales for €56k. Purchases outweigh sales by €922k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 3 share grants and 3 option exercises. In 2025 alone, the filings show 1 purchase and 1 sale.

Most recently, on 8 August 2025, the filings show an open-market purchase worth €978k in CRISPR Therapeutics AG. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.